Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Non-Current Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Non-Current Assets for 16 consecutive years, with $34.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 59.52% to $34.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $188.7 million, a 44.71% decrease, with the full-year FY2024 number at $22.2 million, down 9.8% from a year prior.
  • Non-Current Assets was $34.2 million for Q3 2025 at Harvard Bioscience, down from $35.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $102.0 million in Q1 2021 to a low of $22.2 million in Q4 2024.
  • A 5-year average of $70.3 million and a median of $85.0 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: dropped 1.63% in 2022, then crashed 59.52% in 2025.
  • Harvard Bioscience's Non-Current Assets stood at $37.5 million in 2021, then fell by 19.99% to $30.0 million in 2022, then decreased by 17.98% to $24.6 million in 2023, then fell by 9.8% to $22.2 million in 2024, then soared by 54.17% to $34.2 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Non-Current Assets are $34.2 million (Q3 2025), $35.1 million (Q2 2025), and $34.9 million (Q1 2025).